← Back to Clinical Trials
Recruiting NCT06252935

NCT06252935 Effectiveness and Safety of Collagen Membrane (FormaAid®) in the Treatment of Periodontal Regeneration

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06252935
Status Recruiting
Phase —
Sponsor Maxigen Biotech Inc.
Condition Guided Tissue Regeneration
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-07-30
Primary Completion 2025-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
FormaAidBio-Gide

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-07-30 with a primary completion date of 2025-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to evaluate clinically and radiographically effectiveness and products safety of the collagen membrane (FormaAid®) in the treatment of periodontal regeneration using guided tissue regeneration (GTR) performed by the trained periodontists. The main question it aims to answer are: * The difference of periodontal status: clinical attachment level (CAL), periodontal pocket depth (PPD), gingival recession (GR), gingival Index (GI) and plaque index (PI). * The difference of intrabony defect height. * The difference of gingival tissue thickness and gingival tissue volume. * The incidences of safety indicators. Participants will be randomized into either experiment group or control group, undergo guided tissue regeneration (GTR) surgery at week 1, and re-visited on week 3, 5, 13 and 27 after the GTR surgery. Researchers will compare if the test product is non-inferior to Bio-Gide.

Eligibility Criteria

Inclusion Criteria: * Age between 18 70 years old, male or female * Non current smoker: A person who has not smoked more than 100 cigarettes from the past to the present and has not smoked in the last 30 days. * Patients who have decided to pay at their own expense and require guided tissue regeneration (GTR) for periodontal regeneration * The defect morphology of intrabony defects is 2 or 3 wall intrabony defect. * Periodontal pocket depth ≥ 5mm (probing periodontal depth, PPD, distance from gingival margin to the bottom of the defect). * The height of the bone defect in the X ray image is ≥ 3mm (according to the X ray film intraosseous defect) * The diagnosis of periodontal disease is stage III with either grade B or C. * Patients who are willing to adhere to the study protocol and sign the informed consent form. * Willing to accept evaluation during the trial period and return to clinic and treatment. * Not a person subject to a sentence of guardianship or subject to judicial guardians. Exclusion Criteria: * Have a history of severe allergies or be allergic to collagen. * Those who are known to be positive for human immunodeficiency virus. * Poorly controlled diabetes (untreated or unstable disease status), blood test measurement of glycated hemoglobin greater than 7% * Undergoing chemotherapy three months before agreeing to this experiment. * Patients undergoing meat product desensitization treatment. * Have a documented history of osteoporosis. * Chronic disease, hypertension, hyperlipidemia, cardiovascular disease, and stroke not properly controlled (untreated or unstable disease condition) judged by the investigator at screening. * Suffering from autoimmune diseases or connective tissue diseases, such as systemic lupus erythematosus or dermatomyositis. * Coagulation disorder, lab test prothrombin time (PT) \> 12 sec , or the use of anticoagulants that affects surgery judged by the investigator at screening. * The tooth for which guided tissue regeneration (GTR) surgery is to be performed is determined to be furcation involved by investigator from image evaluation * The tooth for which guided tissue regeneration (GTR) surgery is to be performed is considered unhealthy, exhibiting conditions such as apical lesion, needed endodontic therapy tooth, tooth fracture, etc. etc., as judged by the investigator f rom image evaluation * Oral mucosal abnormalities or poor periodontal health, making it unsuitable for GTR surgical treatment, such as white spots, erythema, oral submucosal fibrosis, lichen planus, verrucous hyperplasia, inflammation, infection, etc. judged by the investigator at screening. * Those whose periodontal cleaning is not in good condition or who are unable to cooperate with periodontal cleaning. Plaque control index (O'Leary index) \>15% * The mobility of the teeth that are to undergo guided tissue regeneration (GTR) surgery is greater than or equal to * Teeth that are to undergo guided tissue regeneration (GTR) surgery have incomplete adjacent teeth on both sides, such as dental prostheses, crowns or bridges, artificial dental implants, or metal fillings. materials, etc., so as to affect the image evaluation. * Others who are not suitable to participate in or continue this clinical trial as assessed by a physician.

Contact & Investigator

Central Contact

LiRong Chen

✉ lirong.chen@mbi.com.tw

📞 +88633287222

Principal Investigator

Cheng-En Sung, Doctor

PRINCIPAL INVESTIGATOR

Tri-Service General Hospital (TSGH)

Frequently Asked Questions

Who can join the NCT06252935 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Guided Tissue Regeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06252935 currently recruiting?

Yes, NCT06252935 is actively recruiting participants. Contact the research team at lirong.chen@mbi.com.tw for enrollment information.

Where is the NCT06252935 trial being conducted?

This trial is being conducted at Taipei, Taiwan.

Who is sponsoring the NCT06252935 clinical trial?

NCT06252935 is sponsored by Maxigen Biotech Inc.. The principal investigator is Cheng-En Sung, Doctor at Tri-Service General Hospital (TSGH). The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology